

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/R62FC7E3011EN.html>

Date: November 2018

Pages: 75

Price: US\$ 3,500.00 (Single User License)

ID: R62FC7E3011EN

Abstracts

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2018'; RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - RAC-alpha serine/threonine-protein kinase is an enzyme encoded by the AKT1 gene. It regulates many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine or threonine phosphorylation of a range of downstream substrates. It regulates the storage of glucose in the form of glycogen by phosphorylating GSK3A and GSK3B resulting in inhibition of its kinase activity.

It act as key modulator of the AKT-mTOR signaling pathway controlling the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of

phosphatidylinositol 3-kinase to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I).

The report 'RAC Alpha Serine/Threonine Protein Kinase - Pipeline Review, H2 2018' outlays comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 6, 2 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Hematological Disorders, Non Malignant Disorders and Other Diseases which include indications Endometrial Cancer, Metastatic Breast Cancer, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Hepatocellular Carcinoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Small-Cell Lung Cancer, Solid Tumor, Anal Cancer, Fallopian Tube Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Lymphoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Orphan Diseases (Rare Diseases), Pancreatic Cancer, Peritoneal Cancer, Proteus Syndrome, Renal Cell Carcinoma, Salivary Gland Cancer, Sickle Cell Disease and Thymoma (Thymic Epithelial Tumor).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B

Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)

The report reviews RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create

effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Overview

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

ArQule Inc

AstraZeneca Plc

Bayer AG

Merck & Co Inc

Merck KGaA

Novartis AG

Rexahn Pharmaceuticals Inc

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Drug Profiles

ARQ-751 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1125976 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

capivasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-2698 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

miransertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-2206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-2206 + selumetinib sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NISC-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RX-0201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RX-0201N - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit AKT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trametinib dimethyl sulfoxide + uprosertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

uprosertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Dormant Products

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) -

Discontinued Products

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Oct 19, 2018: ArQule presents orphan disease clinical data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for its pan-AKT inhibitor, Miransertib (ARQ 092)

Oct 04, 2018: ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics 2018 Annual Meeting

Sep 13, 2018: Miransertib (ARQ 092) granted fast track designation for the treatment of PIK3CA-related overgrowth spectrum (PROS)

May 16, 2018: Merck to Present Poster on M2698 at ASCO 2018

Mar 15, 2018: ArQule to Present Data on miransertib at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Mar 15, 2018: ArQule to Provide Update on ARQ

Nov 01, 2017: FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome

Aug 30, 2017: Merck To Present Data On M2698 At ESMO 2017

Jun 07, 2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases

May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting

Dec 03, 2016: Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting

Jun 06, 2016: Rexahn Pharmaceuticals Presents Clinical Data on Archexin at the 2016

ASCO Annual Meeting

Apr 20, 2016: Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin at the 2016 American Association for Cancer Research Annual Meeting

Apr 20, 2016: Rexahn Pharmaceuticals Presents pre-Clinical Trial Data for Archexin-Nano at the 2016 American Association for Cancer Research Annual Meeting

Feb 08, 2016: Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by ArQule Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bayer AG, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Merck KGaA, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Rexahn Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

ArQule Inc

AstraZeneca Plc

Bayer AG

Merck & Co Inc

Merck KGaA

Novartis AG

Rexahn Pharmaceuticals Inc

I would like to order

Product name: RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/R62FC7E3011EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R62FC7E3011EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970